HealthDay News — Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ ...

The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Lonapegsomatropin demonstrated efficacy outcomes superior to daily somatropin in treatment of pediatric growth hormone deficiency.

Graves disease had similar presentation but a more severe clinical course when isolated than when part of autoimmune polyglandular syndrome.

Asthma is linked to an increased risk of developing knee, hip, and hand OA, particularly among patients with higher social isolation and loneliness.

Assessment of PSA level for three months after radical prostatectomy for prostate cancer may minimize overtreatment.

The National Institutes of Health will no longer fund new research on how climate change affects people’s health.

OGTT demonstrated similar clinical utility as the two-hour OGTT in dysglycemia reclassification among postpartum individuals.

A Chinese woman is the third person in the world living with a pig kidney, and she's doing well after nearly three weeks post-surgery.

Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.

The U.S. Centers for Disease Control and Prevention (CDC) is facing major changes, with five senior leaders stepping down.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.